A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma

Soft Tissue Sarcoma Clinical Trial

Official title:

A Phase IIa Open Label Study Evaluating the Preliminary Efficacy of Intratumoural Tigilanol Tiglate in Advanced and/or Metastatic Soft Tissue Sarcoma of the Extremities and Body Wall.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05755113
• Other study ID #: QB46C-H07
• Secondary ID: U1111-1282-2967
• Status: Recruiting
• Phase: Phase 2
• Start date: April 13, 2023
• Est. completion date: March 2025

Study information

• Verified date: April 2023
• Source: QBiotics Group Limited
• Contact: Head of Human Clinical Operations
• Phone: +61 (0) 738 708 933
• Email: enquiries[@]qbiotics.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase IIa open label study evaluating the preliminary efficacy of intratumoural tigilanol tiglate in advanced and/or metastatic soft tissue sarcoma of the extremities and body wall.

Description:

Primary Objective

1. To evaluate tumour ablation in tumours and/or tumour segments following one or more treatments with tigilanol tiglate.

Secondary Objective

1. To assess the safety and tolerability of intratumoural injections with tigilanol tiglate; and

2. To evaluate systemic exposure through pharmacokinetic (PK) assessment after a single intratumoural injection of tigilanol tiglate.

Exploratory Objectives

1. To evaluate the microenvironment of injected tumours;

2. To evaluate the degree of immune response elicited with intratumoural tigilanol tiglate;

3. To evaluate local recurrence rate.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: March 2025
• Est. primary completion date: July 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Are willing and able to provide written informed consent for the study prior to any protocol-specific procedures and to comply with all local and study requirements.

2. Are = 18 years of age on the day of providing informed consent.

3. Have advanced and/or metastatic disease of the body wall or extremities that is amenable to intratumoural injection either by palpation or under ultrasound guided injection, that has been histologically or pathologically confirmed as an STS. STS located on the scalp may also be considered for treatment.

4. Have an Eastern Cooperative Oncology Group (ECOG) performance status of = 2.

5. Have life expectancy of more than 12 weeks.

6. Have adequate renal and hepatic function as assessed by the Investigator.

7. Female participants who are Women Of Child-Bearing Potential (WOCBP) must have a negative serum pregnancy test at Screening (within 14 days of the first study drug administration), must be willing to use a highly effective contraception from date of consent, throughout the study period and up to 30 days after the last study drug administration, and must not be breastfeeding.

8. Male participants with a potentially fertile female partner are eligible if they have had a vasectomy or are willing to use adequate contraception from prior to commencement of study drug administration, throughout the study period and up to 30 days after the last study drug administration, and must not donate sperm throughout the study period and up to 30 days after the last study drug administration.

Exclusion Criteria:

1. Are planning to receive intratumoural treatment or radiotherapy to any of the tumours intended for injection within 28 days prior to Screening, or during treatment with tigilanol tiglate.

2. Have a tumour intended for injection that is immediately adjacent to, or with infiltration into, any major artery or vein (e.g., if the tumour for injection is located adjacent to the jugular vein).

3. Are receiving or have received other investigational agents or have used an investigational device without undergoing a 28-day (or 5 half-lives, whichever is shorter) wash-out period prior to their first treatment with tigilanol tiglate. These patients must have recovered from all AEs due to previous investigational therapies to = Grade 1 at baseline.

4. Are receiving or have received systemic anticancer therapy, without undergoing a 28-day (or 5 half-lives, whichever is shorter) wash-out period prior to their first treatment with tigilanol tiglate. These patients must have recovered from all AEs due to previous therapies to = Grade 1 at baseline. Patients with = Grade 2 neuropathy may be eligible following discussion with Sponsor Medical Monitor.

5. Have had major surgery within 28 days of their first treatment with tigilanol tiglate or anticipate the need for major surgery during the study period. Minor surgical procedures are permitted, but with sufficient time for wound healing.

6. Have known, active brain metastases and/or carcinomatous meningitis. Participants who have previously treated brain metastases and are neurologically stable can be included.

7. Have any bleeding diathesis or coagulopathy that would make intratumoural injection or biopsy unsafe, or if they are on therapeutic warfarin therapy.

8. Have a history of allergic reactions or severe hypersensitivity (Grade = 3) attributed to tigilanol tiglate or compounds of similar chemical or biologic composition to tigilanol tiglate, any of its excipients or other agents used in the study.

9. In the opinion of the treating Investigator, they are not an appropriate candidate for the study for any reason (e.g., they have known psychiatric or substance abuse disorder that would interfere with their ability to cooperate with the requirements of the study.

Related Conditions & MeSH terms

• Sarcoma
• Soft Tissue Sarcoma

Intervention

Drug:
• Tigilanol Tiglate
Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Cancer Centre	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
QBiotics Group Limited

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Tumour Microenvironment	To assess changes in the tumour microenvironment by looking at the change from baseline of immune cell infiltration in tumour biopsy tissue collected after injection with tigilanol tiglate.	14 days after the first treatment.
Other	Evaluation of Peripheral Blood Mononucleocytes (PBMCs)	Evaluation of Peripheral Blood Mononucleocytes (PBMCs).	24 weeks
Other	Local Recurrence Rate at injection site(s)	Percentage of participants with local recurrence at injection site(s) at 6-months after first treatment.	6 months
Primary	Tumour Response	Proportion of participants who have achieved partial or complete ablation of treated tumour(s) and/or tumour segment(s) following injection(s) with tigilanol tiglate.	6 months
Secondary	Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)	Total number of Adverse Events (AEs) and Serious Adverse Events (SAEs) and number of AEs and SAEs deemed related to tigilanol tiglate.	6 months
Secondary	Systemic Exposure	Evaluation of how much tigilanol tiglate is circulating in the blood after a single injection.	Up to 24 hours after the first dose